journal
MENU ▼
Read by QxMD icon Read
search

Clinical Lung Cancer

journal
https://www.readbyqxmd.com/read/28522158/access-to-cancer-specialist-care-and-treatment-in-patients-with-advanced-stage-lung-cancer
#1
Apar Kishor Ganti, Fred R Hirsch, Murry W Wynes, Arliene Ravelo, Suresh S Ramalingam, Raluca Ionescu-Ittu, Irina Pivneva, Hossein Borghaei
BACKGROUND: Access to specialty care is critical for patients with advanced stage lung cancer. This study assessed access to cancer specialists and cancer treatment in a broad population of patients with advanced stage lung cancer. MATERIALS AND METHODS: Two study samples were extracted from 2 claims databases and analyzed independently: patients aged ≥ 18 years with de novo diagnosis of metastatic lung cancer in the MarketScan database between 2008 and 2014 (commercially insured adult patients; n = 22,268); and patients aged ≥ 65 years in the Surveillance, Epidemiology, and End Results-Medicare database with a diagnosis of advanced non-small-cell lung cancer between 2007 and 2011 (Medicare-insured elderly patients; n = 9651)...
April 26, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28522159/relationship-between-tumor-location-and-outcome-in-patients-with-early-stage-lung%C3%A2-cancer
#2
LETTER
Max Dahele, Ronald A Damhuis
No abstract text is available yet for this article.
April 23, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28502555/nivolumab-in-second-line-treatment-for-advanced-non-small-cell-lung-cancer-with-squamous-cell-histology-a-perspective-based-on-pharmacologic-costs
#3
LETTER
Jacopo Giuliani, Andrea Bonetti
No abstract text is available yet for this article.
April 23, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28479369/genomic-profiling-of-advanced-non-small-cell-lung-cancer-in-community-settings-gaps-and-opportunities
#4
Martin E Gutierrez, Kelly Choi, Richard B Lanman, Edward J Licitra, Stanley M Skrzypczak, Ruth Pe Benito, Tommy Wu, Srikesh Arunajadai, Sukhi Kaur, Harry Harper, Andrew L Pecora, Eric V Schultz, Stuart L Goldberg
BACKGROUND: National guidelines have advocated broad molecular profiling as a part of the standard diagnostic evaluation for advanced non-small cell lung cancer (NSCLC), with the goal of identifying driver mutations for which effective therapies or clinical trials are available. However, adherence to genomic testing guidelines could present challenges to community oncologists. PATIENTS AND METHODS: We performed a retrospective review of genomic testing patterns in patients with nonsquamous NSCLC treated by 89 oncologists at 15 sites throughout New Jersey and Maryland from January 2013 to December 2015...
April 13, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28479368/safety-analyses-of-pemetrexed-cisplatin-and-pemetrexed-maintenance-therapies-in-patients-with-advanced-non-squamous-nsclc-retrospective-analyses-from-2-phase-iii-studies
#5
Corey J Langer, Luis G Paz-Ares, Antoinette J Wozniak, Cesare Gridelli, Filippo de Marinis, Jean-Louis Pujol, Belen San Antonio, Jian Chen, Jingyi Liu, Ana B Oton, Carla Visseren-Grul, Giorgio V Scagliotti
BACKGROUND: In a phase III study, maintenance pemetrexed showed superior survival over placebo (PARAMOUNT) for patients with advanced non-squamous non-small cell lung cancer (NSCLC) who completed 4 cycles of pemetrexed plus cisplatin (PC) induction therapy, with low incidence of treatment-emergent adverse events (TEAEs) generally associated with pemetrexed. Prior analyses did not account for toxicities carried over from induction; thus, the current analysis was developed to understand toxicities that may be attributed to pemetrexed maintenance versus PC induction, and how treatment duration affects toxicity...
April 12, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28465010/local-therapy-for-oligoprogressive-disease-in-patients-with-advanced-stage-non-small-cell-lung-cancer-harboring-epidermal-growth-factor%C3%A2-receptor-mutation
#6
Bo Qiu, Ying Liang, QiWen Li, GuiHong Liu, Fang Wang, ZhaoLin Chen, MengZhong Liu, Ming Zhao, Hui Liu
INTRODUCTION: The effect of local therapy (LT) for oligoprogressive epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) has not been well established. Forty-six patients with stage IIIB/IV EGFR-mutated NSCLC were treated by LT and continuing tyrosine kinase inhibitors (TKIs) for oligoprogression. The median overall survival (OS) and progression-free survival (PFS) after LT were 13.0 and 7.0 months, respectively. EGFR mutation type, sites of LT, and time from first progressive disease (PD) to LT were prognostic of OS after LT...
April 12, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28438510/disparities-in-the-management-of-patients-with-stage-i-small-cell-lung-carcinoma-sclc-a-surveillance-epidemiology-and-end-results-seer-analysis
#7
Zaheer Ahmed, Lara Kujtan, Kevin F Kennedy, John R Davis, Janakiraman Subramanian
INTRODUCTION: Patients with stage I small cell lung carcinoma (SCLC) are candidates for surgery; however, not much is known regarding the utilization of surgical resection in the management of stage I SCLC and the factors that determine the patient's ability to receive surgery. METHODS: The Surveillance, Epidemiology and End Results database was used to identify patients with stage I SCLC from 2007 to 2013. Continuous variables were compared with 1-way analysis of variance, and categorical variables were compared with χ(2) testing...
March 30, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28416261/feasibility-study-of-personalized-peptide-vaccination-for-advanced-small-cell-lung-cancer
#8
Shinjiro Sakamoto, Teppei Yamada, Yasuhiro Terazaki, Koichi Yoshiyama, Shunichi Sugawara, Shinzo Takamori, Satoko Matsueda, Shigeki Shichijo, Akira Yamada, Masanori Noguchi, Kyogo Itoh, Noboru Hattori, Nobuoki Kohno, Tetsuro Sasada
INTRODUCTION: The prognosis of patients with small cell lung cancer (SCLC) remains very poor. Therefore, the development of new therapeutic approaches, including immunotherapies, is desirable. PATIENTS AND METHODS: We conducted a phase II study of personalized peptide vaccination (PPV), in which a maximum of 4 human leukocyte antigen-matched peptides were selected from 31 pooled peptides according to the pre-existing peptide-specific IgG responses before vaccination...
March 24, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28416124/assessment-of-the-external-validity-of-the-national-comprehensive-cancer-network-and-european-society-for-medical-oncology-guidelines-for-non-small-cell-lung-cancer-in-a-population-of-patients-aged-80-years-and-older
#9
REVIEW
Nicolò Matteo Luca Battisti, Marina Sehovic, Martine Extermann
Non-small-cell lung cancer (NSCLC) is a disease of the elderly, who are under-represented in clinical trials. This challenges the external validity of the evidence base for its management and of current guidelines, that we evaluated in a population of older patients. We retrieved randomized clinical trials (RCTs) supporting the guidelines and identified 18 relevant topics. We matched a cohort of NSCLC patients aged older than 80 years from the Moffitt Cancer Center database with the studies' eligibility criteria to check their qualification for at least 2 studies...
March 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28408183/outcomes-of-stereotactic-body-radiotherapy-for-t1-t2n0-small-cell-carcinoma-according-to-addition-of-chemotherapy-and-prophylactic-cranial-irradiation-a-multicenter-analysis
#10
Vivek Verma, Charles B Simone, Pamela K Allen, Steven H Lin
BACKGROUND: Although T1-T2N0 non-small cell lung cancer can be managed with stereotactic body radiotherapy (SBRT) alone, this management has often been extrapolated to T1-T2N0 small cell lung cancer (SCLC). This secondary analysis of a multi-institutional cohort study investigated whether the addition of chemotherapy and prophylactic cranial irradiation (PCI) improved the outcomes for these patients. MATERIALS AND METHODS: All cases of histologically confirmed T1-T2N0M0 SCLC were obtained from 24 institutions' prospectively collected SBRT databases...
March 16, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28385373/computed-tomography-features-of-lung-adenocarcinomas-with-programmed-death-ligand-1-expression
#11
Gouji Toyokawa, Kazuki Takada, Tatsuro Okamoto, Mototsugu Shimokawa, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Shinkichi Takamori, Takaki Akamine, Masakazu Katsura, Fumihiro Shoji, Yoshinao Oda, Yoshihiko Maehara
INTRODUCTION: The development of immune checkpoint inhibitors against programmed death 1 has paved the way for a new era of treatment of lung cancer. Programmed death-ligand 1 (PD-L1) is expected to predict the response of immune checkpoint inhibitors in lung cancer. Predicting PD-L1 expression using a noninvasive method before immunotherapy would, therefore, help identify patients for whom immunotherapy can be successful. PATIENTS AND METHODS: A total of 394 patients with resected lung adenocarcinoma who had undergone preoperative thin-section computed tomography (CT) were analyzed for PD-L1 expression by immunohistochemistry and evaluated to determine the association between PD-L1 expression and CT characteristics, including convergence, surrounding ground glass opacity (GGO), air bronchogram, notching, pleural indentation, spiculation, and cavitation...
March 16, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28385372/enrollment-of-elderly-patients-with-locally-advanced-non-small-cell-lung-cancer-in-multi-institutional-trials-of-proton-beam-radiation-therapy
#12
Vivek Verma, Jean-Claude M Rwigema, Sebastian Adeberg, Charles B Simone
No abstract text is available yet for this article.
March 16, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28373068/stereotactic-body-radiotherapy-for-early-stage-non-small-cell-lung-cancer-in-patients-80-years-and-older-a-multi-center-analysis
#13
Richard J Cassidy, Pretesh R Patel, Xinyan Zhang, Robert H Press, Jeffrey M Switchenko, Rathi N Pillai, Taofeek K Owonikoko, Suresh S Ramalingam, Felix G Fernandez, Seth D Force, Walter J Curran, Kristin A Higgins
BACKGROUND: Stereotactic body radiotherapy (SBRT) is the standard of care for medically inoperable early-stage non-small-cell lung cancer. Despite the limited number of octogenarians and nonagenarians on trials of SBRT, its use is increasingly being offered in these patients, given the aging cancer population, medical fragility, or patient preference. Our purpose was to investigate the efficacy, safety, and survival of patients ≥ 80 years old treated with definitive lung SBRT. METHODS: Patients who underwent SBRT were reviewed from 2009 to 2015 at 4 academic centers...
March 16, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28377206/ablative-therapy-for-oligometastatic-non-small-cell-lung-cancer
#14
REVIEW
Oscar Juan, Sanjay Popat
The oligometastatic state represents a distinct entity among those with metastatic disease and consists of patients with metastases limited in number and location, representing an intermediate state between locally confined and widely metastatic cancer. Although similar, "oligorecurrence" (limited number of metachronous metastases under conditions of a controlled primary lesion) and "oligoprogressive" (disease progression at a limited number of sites with disease controlled at other disease sites) states are distinct entities...
March 14, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28377205/molecular-testing-turnaround-time-for-non-small-cell-lung-cancer-in-routine-clinical%C3%A2-practice-confirms-feasibility-of-cap-iaslc-amp-guideline-recommendations-a-single-center-analysis
#15
Marcello DiStasio, Yigu Chen, Deepa Rangachari, Daniel B Costa, Yael K Heher, Paul A VanderLaan
INTRODUCTION: Molecular testing to identify targetable driver mutations is the standard of care for patients with advanced-stage non-small cell lung cancer. Recent guideline recommendations by the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) established a benchmark turnaround time (TAT) target of 10 working days for results to be available to the treating oncologist and ≤ 3 days for specimens to arrive at a commercial testing laboratory if testing is not performed in-house...
March 14, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28373069/interstitial-lung-disease-associated-with-crizotinib-in-patients-with-advanced-non-small-cell-lung-cancer-independent-review-of-four-profile-trials
#16
Ken Y Yoneda, Judith R Scranton, Michael A Cadogan, Vanessa Tassell, Sashi Nadanaciva, Keith D Wilner, Nicholas S Stollenwerk
INTRODUCTION: Interstitial lung disease (ILD) is a rare, but potentially serious, side effect associated with crizotinib, a tyrosine kinase inhibitor for anaplastic lymphoma kinase-positive (ALK(+)) advanced non-small cell lung cancer. Our objective was to determine the incidence and nature of ILD associated with crizotinib in 4 PROFILE trials (ClinicalTrials.gov identifiers, NCT00585195, NCT00932451, NCT00932893, and NCT01154140). MATERIALS AND METHODS: Grade ≥ 3 respiratory adverse events (AEs) and serious AEs (SAEs) and any grade AEs/SAEs reported as pneumonitis, ILD, or radiation pneumonitis in trials PROFILE 1001, PROFILE 1005, PROFILE 1007, and PROFILE 1014 were evaluated by an expert independent review committee that included a pulmonologist, medical oncologist, and radiologist...
March 14, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28412094/emotional-problems-quality-of-life-and-symptom-burden-in-patients-with-lung-cancer
#17
Eleshia J Morrison, Paul J Novotny, Jeff A Sloan, Ping Yang, Christi A Patten, Kathryn J Ruddy, Matthew M Clark
OBJECTIVES: Lung cancer is associated with a greater symptom burden than other cancers, yet little is known about the prevalence of emotional problems and how emotional problems may be related to the physical symptom burden and quality of life in newly diagnosed patients with lung cancer. This study aimed to identify the patient and disease characteristics of patients with lung cancer experiencing emotional problems and to examine how emotional problems relate to quality of life and symptom burden...
March 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28412093/non-small-cell-lung-cancer-as-a-second-primary-among-patients-with-previous-malignancy-who-is-at-risk
#18
Geena X Wu, Rebecca A Nelson, Jae Y Kim, Dan J Raz
BACKGROUND: Patients with previous malignancies could be at increased risk of non-small cell lung cancer (NSCLC). However, the extent of the risk is unknown for many cancer types; thus, it is unclear who might benefit from screening. MATERIALS AND METHODS: The Surveillance, Epidemiology, and End Results data set from 1992 to 2012 was used to identify patients with previous malignancies who received a diagnosis of NSCLC ≥ 6 months after their initial cancer diagnosis...
March 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28365238/an-open-label-randomized-controlled-phase-ii-study-of-paclitaxel-carboplatin-chemotherapy-with-necitumumab-versus-paclitaxel-carboplatin-alone-in-first-line-treatment-of-patients-with-stage-iv-squamous-non-small-cell-lung-cancer
#19
David R Spigel, Alexander Luft, Henrik Depenbrock, Rodryg Ramlau, Mazen Khalil, Joo-Hang Kim, Carlos Mayo, Grace Yi Chao, Coleman Obasaju, Ronald Natale
BACKGROUND: The combination of necitumumab with gemcitabine-cisplatin significantly improved overall survival (OS) in patients with stage IV squamous non-small-cell lung cancer (NSCLC), in the phase III SQUamous NSCLC treatment with the Inhibitor of EGF REceptor (SQUIRE) trial. Paclitaxel-carboplatin was selected as an alternative standard of care in the current phase II study. PATIENTS AND METHODS: Patients were randomized (stratified according to Eastern Cooperative Oncology Group performance status and sex) 2:1 to ≤ six 3-week cycles (Q3W) of paclitaxel and carboplatin with or without necitumumab...
March 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28342728/comparative-analysis-for-diagnostic-yield-of-small-cell-lung-cancer-by-cytology-and%C3%A2-histology-during-the-same-bronchoscopic%C3%A2-procedure
#20
Wei-Nan Li, Di-Fei Wang, Ya-Bin Zhao, Xue-Shan Qiu, En-Hua Wang, Guang-Ping Wu
BACKGROUND: Biopsy, brushing, and transbronchial needle aspiration (TBNA) are the most common methods used for the diagnosis of small cell lung cancer during the same diagnostic bronchoscopic procedure. However, it is not clear which method provides better results. PATIENTS AND METHODS: A retrospective analysis was performed of 140 patients who had undergone video bronchoscopy for diagnostic purposes. Bronchial brushings were obtained from all subjects. Biopsy specimens were also obtained from all subjects, except for 6 cases that could not be sampled; the TBNA method was used for some special lesions...
March 2, 2017: Clinical Lung Cancer
journal
journal
34772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"